Novartis
India’s Supreme Court rejects patent plea by Novartis for the cancer drug Glivec
By Jeanette Jakobsson | Posted on April 18, 2013
For years, India did not offer any patent protection for chemical compounds, but was obliged to do this after joining the World Trade Organization. In 2005, the patent protection act therefore was amended to also include such compounds, but only if they proved significant clinical efficacy enhancements over already patented compounds, Section 3(d) of the Indian...
Recent contributors
Partner, Attorney at Law, Business Area Manager
Associate, Attorney at Law, European Trademark and Design Attorney
Senior Associate, Patents
Partner, European Patent Attorney, Authorised Swedish Patent Attorney, UPC Representative
Partner, Attorney at Law, Group Vice President
Senior Associate, Attorney at Law